NCT01500018

Study in Healthy Recreational Polydrug Users to Measure the Abuse Potential of TC-5214

A Single-center, Single-dose, Double-blind, Randomized, Placebo- and Active-controlled Crossover Study to Evaluate the Abuse Potential of TC-5214 in Healthy Recreational Polydrug Users

• Status: Withdrawn
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: AstraZeneca · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

This is a single dose, crossover study to assess the abuse potential of TC-5214 compared to placebo, ketamine, and phentermine in healthy recreational polydrug users.

Detailed description

A Single-center, Single-dose, Double-blind, Randomized, Placebo- and Active-controlled Crossover Study to Evaluate the Abuse Potential of TC-5214 in Healthy Recreational Polydrug Users.

Conditions

• Drug Abuse
• Healthy

Interventions

Type	Name	Description
DRUG	TC-5214	Single oral dose of 2 mg
DRUG	TC-5214 Placebo	Single oral dose
DRUG	Ketamine	Single oral dose of 100 mg
DRUG	Phentermine	Single oral dose of 45 mg
DRUG	TC-5214	Single oral dose of 8 mg
DRUG	TC-5214	Single oral dose of 16 mg
DRUG	Phentermine	Single oral dose of 90 mg

Timeline

• Start date: 2012-01-01
• Primary completion: 2012-04-01
• Completion: 2012-04-01
• First posted: 2011-12-26
• Last updated: 2012-03-22